Skip to main navigation

Skip to content

About PDL
Leadership
Investor Relations

About PDL
Leadership
Investor Relations

Investor Updates

PDL BioPharma, Inc > Investor Relations >

Investor Updates

Investor Updates

Please see below.

September 4, 2024 – Letter to Investors Regarding Q2 2024 Results 145.7 KB

May 7, 2024 – Letter to Investors Regarding Q1 2024 Results 170.7 KB

March 5, 2024 – Letter to Investors Regarding Q4 2023 Results 181.9 KB

November 9, 2023 – Letter to Investors Regarding Q3 2023 Results 883 KB

August 21, 2023 – Letter to Investors Regarding Fourth Interim Distribution 251.7 KB

August 18, 2023 - Order Approving Fourth Interim Distribution 225 KB

August 8, 2023 – Letter to Investors Regarding Q2 2023 Results 871.5 KB

May 23, 2023 – Letter to Investors Regarding Q1 2023 Results 867.6 KB

May 11, 2023 – Letter to Investors Regarding Year End 2022 1.1 MB

May 11, 2023 – Financial Statements (Year End 2022) 659.8 KB

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Frequently Asked Questions (FAQ)
Investor Updates
Press Releases
Tax Information
- Common Stock Tax Information
- Convertible Note Tax Information
SEC Filings
Contact Information

Printed Materials
Email Alerts
RSS
Print
Share
Search

Facebook
LinkedIn
Twitter
RSS

Terms of Use
Privacy Policy
Sitemap

© Copyright 2024 PDL BioPHARMA. All Rights Reserved.